- Home
- SKYE vs LLAP Comparison
SKYE vs LLAP Comparison
Compare SKYE & LLAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- LLAP
- Stock Information
- Founded
- SKYE 2012
- LLAP 2013
- Country
- SKYE United States
- LLAP United States
- Employees
- SKYE N/A
- LLAP N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- LLAP Military/Government/Technical
- Sector
- SKYE Health Care
- LLAP Industrials
- Exchange
- SKYE Nasdaq
- LLAP Nasdaq
- Market Cap
- SKYE 172.9M
- LLAP 165.7M
- IPO Year
- SKYE N/A
- LLAP N/A
- Fundamental
- Price
- SKYE $5.84
- LLAP $0.24
- Analyst Decision
- SKYE Strong Buy
- LLAP Buy
- Analyst Count
- SKYE 4
- LLAP 3
- Target Price
- SKYE $19.25
- LLAP $2.58
- AVG Volume (30 Days)
- SKYE 174.2K
- LLAP 9.4M
- Earning Date
- SKYE 08-09-2024
- LLAP 08-12-2024
- Dividend Yield
- SKYE N/A
- LLAP N/A
- EPS Growth
- SKYE N/A
- LLAP N/A
- EPS
- SKYE N/A
- LLAP N/A
- Revenue
- SKYE N/A
- LLAP $133,107,000.00
- Revenue This Year
- SKYE N/A
- LLAP $8.71
- Revenue Next Year
- SKYE N/A
- LLAP $34.59
- P/E Ratio
- SKYE N/A
- LLAP N/A
- Revenue Growth
- SKYE N/A
- LLAP 10.75
- 52 Week Low
- SKYE $1.44
- LLAP $0.23
- 52 Week High
- SKYE $19.41
- LLAP $1.62
- Technical
- Relative Strength Index (RSI)
- SKYE 49.83
- LLAP 24.59
- Support Level
- SKYE $5.67
- LLAP $0.24
- Resistance Level
- SKYE $6.69
- LLAP $0.30
- Average True Range (ATR)
- SKYE 0.68
- LLAP 0.02
- MACD
- SKYE 0.10
- LLAP 0.01
- Stochastic Oscillator
- SKYE 43.40
- LLAP 2.95
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About LLAP Terran Orbital Corporation
Terran Orbital Corp is a manufacturer of satellite products primarily serving the aerospace and defense industries. The company provide end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of our military, civil, and commercial customers. Geographically company operates in United States and Europe. Majority of the revenue is generated from United States.